Matinas BioPharma Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Matinas BioPharma Holdings has a total shareholder equity of $19.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $25.1M and $5.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$13.76m |
Equity | US$19.25m |
Total liabilities | US$5.86m |
Total assets | US$25.10m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6LJ's short term assets ($15.5M) exceed its short term liabilities ($2.6M).
Long Term Liabilities: 6LJ's short term assets ($15.5M) exceed its long term liabilities ($3.2M).
Debt to Equity History and Analysis
Debt Level: 6LJ is debt free.
Reducing Debt: 6LJ has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6LJ has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 6LJ is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.